NASDAQ:HOOK HOOKIPA Pharma (HOOK) Stock Price, News & Analysis $0.91 -0.03 (-2.77%) As of 08/29/2025 03:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HOOKIPA Pharma Stock (NASDAQ:HOOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HOOKIPA Pharma alerts:Sign Up Key Stats Today's Range$0.90▼$0.9450-Day Range$0.82▼$1.3052-Week Range$0.72▼$5.30Volume7,265 shsAverage Volume121,796 shsMarket Capitalization$11.09 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York. Read More HOOKIPA Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreHOOK MarketRank™: HOOKIPA Pharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 340th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingHOOKIPA Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHOOKIPA Pharma has received no research coverage in the past 90 days.Read more about HOOKIPA Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for HOOKIPA Pharma are expected to decrease in the coming year, from ($1.75) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HOOKIPA Pharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HOOKIPA Pharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHOOKIPA Pharma has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about HOOKIPA Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of HOOKIPA Pharma has been sold short.Short Interest Ratio / Days to CoverHOOKIPA Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HOOKIPA Pharma has recently decreased by 81.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHOOKIPA Pharma does not currently pay a dividend.Dividend GrowthHOOKIPA Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.10% of the float of HOOKIPA Pharma has been sold short.Short Interest Ratio / Days to CoverHOOKIPA Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HOOKIPA Pharma has recently decreased by 81.28%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentHOOKIPA Pharma has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for HOOKIPA Pharma this week, compared to 0 articles on an average week.Search Interest1 people have searched for HOOK on MarketBeat in the last 30 days. MarketBeat Follows1 people have added HOOKIPA Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, HOOKIPA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,362.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of HOOKIPA Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of HOOKIPA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HOOKIPA Pharma's insider trading history. Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HOOKIPA Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HOOK Stock News HeadlinesHOOKIPA Pharma (NASDAQ:HOOK) Shares Down 1.5% - Should You Sell?August 29 at 2:37 AM | americanbankingnews.comHOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead SciencesJuly 18, 2025 | quiverquant.comQTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common StockJuly 18, 2025 | globenewswire.comHookipa Pharma Inc News (HOOK) - Investing.comJune 24, 2025 | investing.comGilead (GILD) to Acquire HOOK for $10 millionMay 23, 2025 | msn.comGilead to buy certain Hookipa Pharma assets for up to $10MMay 22, 2025 | msn.comHookipa Pharma (HOOK) Receives a Hold from RBC CapitalMarch 4, 2025 | markets.businessinsider.comSee More Headlines HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? HOOKIPA Pharma's stock was trading at $2.01 at the start of the year. Since then, HOOK stock has decreased by 54.7% and is now trading at $0.91. How were HOOKIPA Pharma's earnings last quarter? HOOKIPA Pharma Inc. (NASDAQ:HOOK) issued its earnings results on Thursday, May, 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by $0.62. HOOKIPA Pharma had a negative net margin of 785.66% and a negative trailing twelve-month return on equity of 120.09%. When did HOOKIPA Pharma's stock split? Shares of HOOKIPA Pharma reverse split before market open on Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did HOOKIPA Pharma IPO? HOOKIPA Pharma (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of HOOKIPA Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HOOKIPA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/15/2025Today8/30/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOOK CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees160Year FoundedN/APrice Target and Rating Average Price Target for HOOKIPA Pharma$4.50 High Price Target$7.00 Low Price Target$2.00 Potential Upside/Downside+394.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($5.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.50 million Net Margins-785.66% Pretax Margin-785.15% Return on Equity-120.09% Return on Assets-77.14% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual Sales$9.35 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.21Miscellaneous Outstanding Shares12,189,000Free Float11,787,000Market Cap$11.09 million OptionableOptionable Beta0.93 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:HOOK) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.